-DOCSTART- -X- O
Ocular -X- _ B-Intervention
gene -X- _ I-Intervention
therapy -X- _ I-Intervention
is -X- _ O
rapidly -X- _ O
becoming -X- _ O
a -X- _ O
reality. -X- _ O
By -X- _ O
November -X- _ O
2012 -X- _ O
, -X- _ O
approximately -X- _ O
28 -X- _ O
clinical -X- _ O
trials -X- _ O
were -X- _ O
approved -X- _ O
to -X- _ O
assess -X- _ O
novel -X- _ O
gene -X- _ O
therapy -X- _ O
agents. -X- _ O
Viral -X- _ O
infections -X- _ O
such -X- _ O
as -X- _ O
herpetic -X- _ B-Patient
keratitis -X- _ I-Patient
caused -X- _ O
by -X- _ O
herpes -X- _ O
simplex -X- _ O
virus -X- _ O
1 -X- _ O
( -X- _ O
HSV-1 -X- _ O
) -X- _ O
can -X- _ O
cause -X- _ O
serious -X- _ O
complications -X- _ O
that -X- _ O
may -X- _ O
lead -X- _ O
to -X- _ O
blindness. -X- _ O
Recurrence -X- _ O
of -X- _ O
the -X- _ O
disease -X- _ O
is -X- _ O
likely -X- _ O
and -X- _ O
cornea -X- _ O
transplantation -X- _ O
, -X- _ O
therefore -X- _ O
, -X- _ O
might -X- _ O
not -X- _ O
be -X- _ O
the -X- _ O
ideal -X- _ O
therapeutic -X- _ O
solution. -X- _ O
This -X- _ O
paper -X- _ O
will -X- _ O
focus -X- _ O
on -X- _ O
the -X- _ O
current -X- _ O
situation -X- _ O
of -X- _ O
ocular -X- _ B-Intervention
gene -X- _ I-Intervention
therapy -X- _ I-Intervention
research -X- _ O
against -X- _ O
herpetic -X- _ B-Patient
keratitis -X- _ I-Patient
, -X- _ O
including -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
viral -X- _ O
and -X- _ O
nonviral -X- _ O
vectors -X- _ O
, -X- _ O
routes -X- _ O
of -X- _ O
delivery -X- _ O
of -X- _ O
therapeutic -X- _ O
genes -X- _ O
, -X- _ O
new -X- _ O
techniques -X- _ O
, -X- _ O
and -X- _ O
key -X- _ O
research -X- _ O
strategies. -X- _ O
Whereas -X- _ O
the -X- _ O
correction -X- _ O
of -X- _ O
inherited -X- _ O
diseases -X- _ O
was -X- _ O
the -X- _ O
initial -X- _ O
goal -X- _ O
of -X- _ O
the -X- _ O
field -X- _ O
of -X- _ O
gene -X- _ O
therapy -X- _ O
, -X- _ O
here -X- _ O
we -X- _ O
discuss -X- _ O
transgene -X- _ O
expression -X- _ O
, -X- _ O
gene -X- _ O
replacement -X- _ O
, -X- _ O
silencing -X- _ O
, -X- _ O
or -X- _ O
clipping. -X- _ O
Gene -X- _ B-Intervention
therapy -X- _ I-Intervention
of -X- _ O
herpetic -X- _ B-Patient
keratitis -X- _ I-Patient
previously -X- _ O
reported -X- _ O
in -X- _ O
the -X- _ O
literature -X- _ O
is -X- _ O
screened -X- _ O
emphasizing -X- _ O
candidate -X- _ O
gene -X- _ O
therapy -X- _ O
targets. -X- _ O
Commonly -X- _ O
adopted -X- _ O
strategies -X- _ O
are -X- _ O
discussed -X- _ O
to -X- _ B-Outcome
assess -X- _ I-Outcome
the -X- _ I-Outcome
relative -X- _ I-Outcome
advantages -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
protective -X- _ I-Outcome
therapy -X- _ I-Outcome
using -X- _ O
antiviral -X- _ O
drugs -X- _ O
and -X- _ O
the -X- _ O
common -X- _ O
gene -X- _ O
therapy -X- _ O
against -X- _ O
long-term -X- _ O
HSV-1 -X- _ O
ocular -X- _ O
infections -X- _ O
signs -X- _ O
, -X- _ O
inflammation -X- _ O
and -X- _ O
neovascularization. -X- _ O
Successful -X- _ O
gene -X- _ B-Intervention
therapy -X- _ I-Intervention
can -X- _ O
provide -X- _ O
innovative -X- _ O
physiological -X- _ O
and -X- _ O
pharmaceutical -X- _ O
solutions -X- _ O
against -X- _ O
herpetic -X- _ B-Patient
keratitis -X- _ I-Patient
. -X- _ O

